This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Harpole, D. H. Articles by Allegra, C. Search for Related Content PubMed PubMed Citation Articles by Harpole, D. H., Jr. Articles by Allegra, C.

The Prognostic Value of Molecular Marker Analysis in Patients Treated with Trimodality Therapy for Esophageal Cancer

Thoracic Oncology Program [D. H. H., M-B. M., T. A., T. A. D.] and Department of Pathology [T. S.], Duke University Medical Center, and Division of Cancer Biostatistics, Duke Comprehensive Cancer Center [J. H.], Durham, North Carolina 27710, and National Cancer Institute, NIH, Bethesda, Maryland [A. P., I. L., C. A.]

The purpose of this study was to define the prognostic value of a group of molecular tumor markers in a well-staged population of patients treated with trimodality therapy for esophageal cancer. The original pretreatment paraffin-embedded endoscopic esophageal tumor biopsy material was obtained from 118 patients treated with concurrent cisplatin + 5-fluorouracil (5-FU) + 45 Gy radiation followed by resection from 1986 until 1997 at the Duke University Comprehensive Cancer Center. Three markers of possible platinum chemotherapy association [metallothionein (MT), glutathione S-transferase- (GST-), P-glycoprotein (P-gp or multidrug resistance)] and one marker of possible 5-FU association [thymidylate synthase (TS)] were measured using immunohistochemistry. The median cancer-free survival was 25.0 months, with a significantly improved survival for the 38 patients who had a complete response (P < 0.001). High-level expression of GST-, P-gp, and TS were associated with a decreased survival. MT was not significant in this population. Multivariate analysis identified high-level expression in two of the platinum markers (GST- and P-gp) and the 5-FU marker TS as independent predictors of early recurrence and death. In conclusion, this investigation measured three possible markers associated with platinum and one possible marker associated with 5-FU in a cohort of esophageal cancer patients. Independent prognostic significance was observed, which suggests that it may be possible to predict which patients may benefit most from trimodality therapy. These data need to be reproduced in a prospective investigation.

This article has been cited by other articles:

				P. Ceppi, M. Volante, A. Ferrero, L. Righi, I. Rapa, R. Rosas, A. Berruti, L. Dogliotti, G. V. Scagliotti, and M. Papotti Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors Clin. Cancer Res., February 15, 2008; 14(4): 1059 - 1064. [Abstract] [Full Text] [PDF]

				K. Ott, W. A. Weber, F. Lordick, K. Becker, R. Busch, K. Herrmann, H. Wieder, U. Fink, M. Schwaiger, and J.-R. Siewert Metabolic Imaging Predicts Response, Survival, and Recurrence in Adenocarcinomas of the Esophagogastric Junction J. Clin. Oncol., October 10, 2006; 24(29): 4692 - 4698. [Abstract] [Full Text] [PDF]

				X. Wu, J. Gu, T.-T. Wu, S. G. Swisher, Z. Liao, A. M. Correa, J. Liu, C. J. Etzel, C. I. Amos, M. Huang, et al. Genetic Variations in Radiation and Chemotherapy Drug Action Pathways Predict Clinical Outcomes in Esophageal Cancer J. Clin. Oncol., August 10, 2006; 24(23): 3789 - 3798. [Abstract] [Full Text] [PDF]

				W. P. Tew, D. P. Kelsen, and D. H. Ilson Targeted Therapies for Esophageal Cancer Oncologist, September 1, 2005; 10(8): 590 - 601. [Abstract] [Full Text] [PDF]

				J.-M. Lee, M.-T. Wu, Y.-C. Lee, S.-Y. Yang, J.-S. Chen, H.-H. Hsu, P.-M. Huang, S.-W. Kuo, C.-J. Lee, and C.-J. Chen Association of GSTP1 Polymorphism and Survival for Esophageal Cancer Clin. Cancer Res., July 1, 2005; 11(13): 4749 - 4753. [Abstract] [Full Text] [PDF]

				M.-B. Moore Joshi, Y. Shirota, K. D. Danenberg, D. H. Conlon, D. S. Salonga, J. E. Herndon II, P. V. Danenberg, and D. H. Harpole Jr. High Gene Expression of TS1, GSTP1, and ERCC1 Are Risk Factors for Survival in Patients Treated with Trimodality Therapy for Esophageal Cancer Clin. Cancer Res., March 15, 2005; 11(6): 2215 - 2221. [Abstract] [Full Text] [PDF]

				M. K. Gibson, S. C. Abraham, T.-T. Wu, B. Burtness, R. F. Heitmiller, E. Heath, and A. Forastiere Epidermal Growth Factor Receptor, p53 Mutation, and Pathological Response Predict Survival in Patients with Locally Advanced Esophageal Cancer Treated with Preoperative Chemoradiotherapy Clin. Cancer Res., December 15, 2003; 9(17): 6461 - 6468. [Abstract] [Full Text] [PDF]

				Y. C. Hu, R. A. Komorowski, S. Graewin, G. Hostetter, O.-P. Kallioniemi, H. A. Pitt, and S. A. Ahrendt Thymidylate Synthase Expression Predicts the Response to 5-Fluorouracil-based Adjuvant Therapy in Pancreatic Cancer Clin. Cancer Res., September 15, 2003; 9(11): 4165 - 4171. [Abstract] [Full Text] [PDF]

				K. R. Brooks, K. To, M.-B. M. Joshi, D. H. Conlon, J. E. Herndon II, T. A. D'Amico, and D. H. Harpole Jr Measurement of chemoresistance markers in patients with stage iii non-small cell lung cancer: a novel approach for patient selection Ann. Thorac. Surg., July 1, 2003; 76(1): 187 - 193. [Abstract] [Full Text] [PDF]

				T. A. Aloia, D. H. Harpole Jr, C. E. Reed, C. Allegra, M.-B. H. Moore, J. E. Herndon II, and T. A. D'Amico Tumor marker expression is predictive of survival in patients with esophageal cancer Ann. Thorac. Surg., September 1, 2001; 72(3): 859 - 866. [Abstract] [Full Text] [PDF]